About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

BM2216 Extended-Release Tablets

Company: Zhejiang Anglikang Pharmaceutical Co., Ltd.
Mechanism: Mechanism not yet reported
Route: Route not yet reported
Recruiting trials: None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details

Completed NCT NCT06846567

Phase I Study of BM2216 ER vs. Melogabalin Besilate: Safety, PK, and Food Effect in Healthy Adults

Not yet reported Zhejiang Anglikang Pharmaceutical Co., Ltd. 66 participants Est. completion 2025-01-12 1 site Stand-alone

Other conditions: Diabetic Neuropathies, Diabetes Mellitus
View official trial listing →

Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

ClinicalTrials.gov — NCT06846567

Also known as: BM2216 Extended-Release Tablets, BM2216 Extended-Release Tablets(11mg), BM2216 Extended-Release Tablets(16.5mg), BM2216 Extended-Release tablets（5.5mg）

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.